CWM
TXMD icon

Castle Wealth Management’s TherapeuticsMD TXMD Stock Holding History

Castle Wealth Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20
Closed – – 594
2022
Q3 		$0 Hold
20
– – ﹤0.01% 735
2022
Q2 		$0 Buy
+20
New +$191 ﹤0.01% 704

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Castle Wealth Management's TXMD Position: Q4 2022 in Review

Castle Wealth Management sold out of TherapeuticsMD (TXMD) in Q4 2022, closing a stake of 20 shares.

Castle Wealth Management first reported a position in TXMD in Q2 2022 and held it in 2 quarters. The position peaked at $0 in Q3 2022. 44 funds tracked by Wall St. Rank hold TXMD as of Q4 2022.

  • Castle Wealth Management reported no remaining TherapeuticsMD position as of Q4 2022 after selling out during the quarter.
  • Castle Wealth Management sold 20 TherapeuticsMD shares in Q4 2022.
  • Castle Wealth Management first reported a position in TherapeuticsMD in Q2 2022 and held it in 2 quarters.
  • Castle Wealth Management's TherapeuticsMD position peaked at $0 in Q3 2022.
  • 44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2022.

Based on Castle Wealth Management's 13F filing for Q4 2022, filed 9 Feb 2023.